Stoke Therapeutics (STU:0GT) Total Liabilities : €55.15 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Total Liabilities?

Stoke Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 was €55.15 Mil.

Stoke Therapeutics's quarterly Total Liabilities increased from Mar. 2024 (€59.65 Mil) to Jun. 2024 (€60.43 Mil) but then declined from Jun. 2024 (€60.43 Mil) to Sep. 2024 (€55.15 Mil).

Stoke Therapeutics's annual Total Liabilities increased from Dec. 2021 (€18.66 Mil) to Dec. 2022 (€67.23 Mil) but then declined from Dec. 2022 (€67.23 Mil) to Dec. 2023 (€63.07 Mil).

Stoke Therapeutics Total Liabilities Historical Data

The historical data trend for Stoke Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Total Liabilities Chart

Stoke Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3.89

9.74

18.66

67.23

63.07

Stoke Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															62.68	63.07	59.65	60.43	55.15

Stoke Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Stoke Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	28.261	+	(0	+	4.479
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	30.329	+	0)
	=	63.07

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	209.39	-	146.321
	=	63.07

Stoke Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	44.928	+	(0	+	2.749
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	7.47	+	0)
	=	55.15

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	264.28	-	209.134
	=	55.15

Stoke Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Stoke Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

STOK:USA 0GT:Germany

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Stoke Therapeutics Headlines

No Headlines